Sort
39,280 grants matching “leukemia”
Altered Communication between the nucleus and the mitochondria under oncogenic states
$387,731Michael P Rout · Rockefeller University · R01 · FY2021 · CA
Transcriptional Mechanism of BRD4 in Solid Tumor
$387,731Ming-Ming Zhou · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
Function and targeting of a stable transcription factor complex in leukemia
$387,731Robert G Roeder · Rockefeller University · R01 · FY2020 · CA
Altered Communication between the nucleus and the mitochondria under oncogenic states
$387,731Michael P Rout · Rockefeller University · R01 · FY2020 · CA
Function and targeting of a stable transcription factor complex in leukemia
$387,731Robert G Roeder · Rockefeller University · R01 · FY2018 · CA
The Discovery of Human Peptide Encoding Genes
$387,730Alan Saghatelian · Harvard University · R01 · FY2012 · GM
GENE EXPRESSION PROFILING OF UNKNOWN PRIMARY CANCERS
$387,728Stanford University · R33 · FY2001 · CA
Computational Structure-Based Protein Design
$387,721Bruce R. Donald · Duke University · R01 · FY2016 · GM
Targeting Ceramide Glycosylation in AML
$387,720Myles C Cabot · University Of Virginia · P01 · FY2017 · CA
Targeting Ceramide Glycosylation in AML
$387,720Myles C Cabot · University Of Virginia · P01 · FY2016 · CA
LEUKEMOGENESIS BY ABL AND OTHER ONCOGENES
$387,715California Institute Of Technology · R01 · FY2003 · CA
High Resolution Assembly Structure of the Nuclear Pore Complex
$387,712Thomas U Schwartz · Massachusetts Institute Of Technology · R01 · FY2016 · GM
GABP Transcription Factor in Myeloid Differentiation
$387,675Alan G Rosmarin · Univ Of Massachusetts Med Sch Worcester · R01 · FY2008 · HL
IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells
$387,630James V Degregori · University Of Colorado Denver · R01 · FY2024 · CA
IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells
$387,630James V Degregori · University Of Colorado Denver · R01 · FY2025 · CA
Pediatric Preclinical Testing Consortium - Leukemia
$387,584Richard B Lock · University Of New South Wales · U01 · FY2019 · CA
PROJECT 3: A High Content Clinical Trial of the MEK inhibitor Trametinib in JMML
$387,575Kevin M Shannon · Indiana University Indianapolis · U54 · FY2024 · CA
Transcription Factor Mutants of Yeast
$387,570Karen M Arndt · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · GM
Understanding MORF-mediated hematological gene regulatory mechanisms
$387,536Tatiana G Kutateladze · University Of Colorado Denver · R01 · FY2025 · GM
Immuno and Epigenetics of Hematopoietic Cell Transplantation
$387,519Effie W Petersdorf · Fred Hutchinson Cancer Research Center · R01 · FY2021 · CA
PROJECT 3: A High Content Clinical Trial of the MEK inhibitor Trametinib in JMML
$387,509Kevin M Shannon · Indiana University Indianapolis · U54 · FY2021 · CA
Monokine Gene Expression/Regulation in Lung Injury
$387,500Steven Lynn Kunkel · University Of Michigan At Ann Arbor · R01 · FY2017 · HL
Aberrant Splice Variants as Potential Precision Biomarkers for Aggressive Prostate Cancers in African American Patients
$387,500Bi-Dar Wang · University Of Maryland Eastern Shore · SC1 · FY2020 · GM
Shp2 and Pten in Leukemia and Anemia
$387,500Gen-Sheng Feng · University Of California, San Diego · R01 · FY2017 · HL
Aberrant Splice Variants as Potential Precision Biomarkers for Aggressive Prostate Cancers in African American Patients
$387,500Bi-Dar Wang · University Of Maryland Eastern Shore · SC1 · FY2022 · GM